Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award
February 03, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Participation in February Investor Conferences
February 02, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
January 25, 2022 08:00 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 06, 2022 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
January 04, 2022 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development
December 22, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and...
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
November 23, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
November 22, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
November 09, 2021 16:05 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces Participation in November Investor Conferences
November 04, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...